Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.

Dillon B, Naidoo B, Knight H, Clark P.

Lancet Oncol. 2012 Aug;13(8):764-5. No abstract available.

PMID:
23024988
[PubMed - indexed for MEDLINE]
2.

Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.

Zhu J, Li T, Wang X, Ye M, Cai J, Xu Y, Wu B.

BMC Cancer. 2013 Jan 29;13:39. doi: 10.1186/1471-2407-13-39.

PMID:
23360224
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.

Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, Creeden J, de la Orden M.

J Int Med Res. 2010 Jan-Feb;38(1):9-21.

PMID:
20233509
[PubMed - indexed for MEDLINE]
4.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
[PubMed - indexed for MEDLINE]
5.

Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.

Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB; NCIC Clinical Trials Group Working Group on Economic Analysis.

J Natl Cancer Inst. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16.

PMID:
20160168
[PubMed - indexed for MEDLINE]
Free Article
6.

[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].

Moldvay J.

Magy Onkol. 2007;51(3):191-6. Epub 2007 Oct 7. Hungarian.

PMID:
17922058
[PubMed - indexed for MEDLINE]
Free Article
7.

Clinical and economic review of erlotinib in non-small-cell lung cancer.

Yeung K, Carlson JJ.

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):411-23. doi: 10.1586/erp.12.42. Review.

PMID:
22971028
[PubMed - indexed for MEDLINE]
8.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
9.

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.

Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL.

Value Health. 2009 Jan-Feb;12(1):20-7. doi: 10.1111/j.1524-4733.2008.00415.x. Epub 2008 Jul 18.

PMID:
18647257
[PubMed - indexed for MEDLINE]
10.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
[PubMed - indexed for MEDLINE]
Free Article
11.

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES.

J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28.

PMID:
20038723
[PubMed - indexed for MEDLINE]
Free Article
12.

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.

Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S.

Lung Cancer. 2012 Jun;76(3):472-7. doi: 10.1016/j.lungcan.2011.12.003. Epub 2012 Jan 9.

PMID:
22226627
[PubMed - indexed for MEDLINE]
13.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930. Epub 2009 May 4.

PMID:
19414683
[PubMed - indexed for MEDLINE]
Free Article
14.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
[PubMed - indexed for MEDLINE]
15.

Gefitinib plus docetaxel in non-small-cell lung cancer.

Costa DB, Kobayashi S.

Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60193-8. No abstract available.

PMID:
19217979
[PubMed - indexed for MEDLINE]
16.

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.

Mazzoni F, Rotella V, Pratesi N, Boni L, Simi L, Orlando C, Comin CE, Maddau C, Di Costanzo F.

Tumori. 2011 Mar-Apr;97(2):160-5. doi: 10.1700/667.7777.

PMID:
21617709
[PubMed - indexed for MEDLINE]
17.

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.

J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. Erratum in: J Clin Oncol. 2011 Dec 10;29(35):4725.

PMID:
21969500
[PubMed - indexed for MEDLINE]
Free Article
18.

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

Baty F, Rothschild S, Früh M, Betticher D, Dröge C, Cathomas R, Rauch D, Gautschi O, Bubendorf L, Crowe S, Zappa F, Pless M, Brutsche M; Swiss Group for Clinical Cancer Research.

PLoS One. 2013 Sep 10;8(9):e72966. doi: 10.1371/journal.pone.0072966. eCollection 2013.

PMID:
24039832
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.

PMID:
21684626
[PubMed - indexed for MEDLINE]
20.

[Pharmacoeconomic analysis of gefitinib therapy in patients with non-cell cell lung cancer].

Protsenko SA, Rudakova AV, Moiseenko FV, Levchenko EV, Matsko DE, Ivantsov AO, Semënov II, Ievleva AG, Mitiushkina NV, Togo AV, Novik AV, Imianitov EN, Moiseenko VM.

Vopr Onkol. 2012;58(3):352-8. Russian.

PMID:
22888650
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk